Home|Journals|Articles by Year|Audio Abstracts RSS - TOC
 

Original Article



Concomitant administration of atorvastatin with N-acetylcysteine mitigates liver injury and steatosis in experimental non-alcoholic fatty liver disease

Naglaa M. El-Lakkany, Sayed H. Seif el-Din, Abdel-Nasser A. Sabra, Olfat A. Hammam, Fatma A. Ebeid.




Abstract

Although numerous efforts have been directed towards searching for new treatments against non-alcoholic fatty liver disease (NAFLD), there are no approved pharmacologic agents up to date. This study evaluates the therapeutic effect of concomitant administration of atorvastatin (ATO) and N-Acetylcysteine (NAC) with/without diet control. Nine groups of rats were divided into; normal, rats fed on high-fat diet for 12 weeks (NAFLD-HFD model), HFD-rats switched to regular diet (NAFLD-RD model), NAFLD-HFD or -RD rats treated with either ATO or NAC orally with 30 or 500 mg/kg/day respectively or both for 8 weeks. NAFLD-HFD rats exhibited remarkable steatosis with lobular inflammation, hepatocytes vacuolation and fibrosis, as well as significant changes in lipid profile, oxidative stress and adipocytokines and these manifestations were less prominent in the HFD-RD group. ATO and NAC combination with diet control has the added benefits on ameliorating lipid levels, liver enzymes, oxidative stress, hepatic steatosis (9.01% ± 1.66% vs 13.21% ± 2.20% for ATO and 25.60% ± 2.11% for NAC), inflammation, hepatocyte vacuolation and fibrosis versus each drug separately. Conclusion; ATO and NAC concomitant therapy has a greater effect on NAFLD as compared to monotherapy and is recommended for further investigation in clinical trials.

Key words: High fat diet; Atorvastatin; N-acetylcysteine; Adipocytokines; lipid profile; oxidative stress.






Full-text options


Share this Article



Online Article Submission
• ejmanager.com
• ojshosting.net




eJManager.com
Review(er)s Central
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.